A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers

Wounds

Volumn 14, Issue 4, 2002, Pages 142-149

  Steinberg, John ^a   Beusterien, Kathleen ^b   Plante, Kathryn ^b   Nordin, Jennifer ^b   Chaikoff, Elliott ^c   Arcona, Stephen ^d   Kim, John ^e   Belletti, Daniel A ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UK   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e DUKE UNIVERSITY   (United States)

^f Clinical Performance Improvement Associates of the Lehigh Valley   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27144470717     PISSN: 10447946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Harrington C, Zagari MJ, Corea J, Klitenic J. A cost analysis of diabetic lower-extremity ulcers. Diabetes Care 2000;23:1333-2338.
2. Ollendorf DA, Kostanos JG, Wishner WJ, et al. Potential economic benefits of lower-extremity amputation prevention strategies in diabetes. Diabetes Care 1998;21:1240-5.
3. Reiber GE, Lisky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1995;176 (suppl 2A) 5S-10S.
4. Veves A, Falanga V, Armstrong DG, Sabolinski MS. Graftskin, a human skin equivalent, is effective in the management of noninfected, neuropathic, diabetic foot ulcers: A prospective, randomized, multicenter, clinical trial. Diabetes Care 2001;24:290-5.
5. Hsiao WC, Braun P, Dunn D, Becker E. Resource-based relative values: An overview. J Am Med Assoc 1988;260:2347-53.
6. Medicaid pharmacy-actual acquisition cost of prescription drug products for brand name drugs. Office of Inspector General Reports and Advisory Opinions. 1997;April .
7. Gardiner J, Hogan A, Holmes-Rovner M, et al. Confidence intervals for cost-effectiveness ratios. Medical Decision Making 1995;15:254-63.
8. Allenet B, Paree F, Lebrun T, et al. Cost-effectiveness modeling of Dermagraft for treatment of diabetic foot ulcers in the French context. Diabetes & Metabolism 2000;26:125-32.
9. Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic ulcers: A pooled analysis. Arch Dermatol 2000;1136(12):1531-5.
10. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and costs of foot ulcers in patients with diabetes. Diabetes Care 1999;22:382-7.
11. Frykberg RG, Armstrong DG, Giurini, et al. Diabetic foot disorders: A clinical practice guideline. J Foot Ankle Surg 2000;39(5 suppl):S1-60.
12. Hogge J, Krasner D, Nguyen H, et al. The potential benefits of advanced therapeutic modalities in the treatment of diabetic foot wounds. J Am Podiatric Med Assoc 2000;90(2):57-65 .
13. Robson MC, Hill DP, Woodske ME, Steed DL. Wound healing trajectories as predictors of effectiveness of therapeutic agents. Arch Surg 2000;135(7):773-7 .
14. Apelqvist J, Ragnarson-Tennvall G, Larsson J, Persson U. Long-term costs for foot ulcers in a multidisciplinary setting. Foot Ankle Intern 1995;16(7):388-94.